Beyond Biotech - the podcast from Labiotech Labiotech

RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. 
The company invests in both public and private companies across their entire life cycle, with a focus on those addressing next-generation gene and RNA therapies, rare diseases, targeted oncological, cardiovascular, and neurological disorders, and more.

To get an overview of what’s happening in financing for biotech companies currently, we had a conversation with Stephanie Sirota, chief business officer of RTW Investments.

01:11-04:18: About RTW Investments
04:18-06:45: What kind of biotech companies do you invest in?
06:45-08:31: How do you evaluate biotech companies?
08:31-11:36: How hands-on are you with companies you invest in?
11:36-14:08: How can companies raise funds currently?
14:08-16:05: Are there any undervalued sectors in biotech?
16:05-17:52: How important are M&As?
17:52-18:30: Is there a trend with M&As?
18:30-19:46: What is the state of the market with IPOs?
19:46-21:21: What are the major trends in biotech in 2024?
21:21-22:17: How could the US elections affect biotech funding?
22:17-24:41: What is the royalties market?
24:41-26:12: Are there regional differences?
26:12-27:52: Getting good biotech deals today

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain.
The Doloromics pipeline is built upon a proprietary discovery and validation platform DOLOReS. 


Jackson Brougher, chief scientific officer and co-founder of Doloromics, is our guest on this week’s Beyond Biotech podcast.

00:46-04:41: About Doloromics
04:41-07:09: What is chronic pain?
07:09-08:30: How challenging is the subjectivity of pain?
08:30-11:04: What is nociception?
11:04-12:23: The challenges of treating pain
12:23-16:35: Is chronic pain a disease?
16:35-19:57: What is VX-548?
19:57-22:17: Monoclonal antibodies and CGRPs
22:17-26:22: How have recent advances in genomic technologies advanced the understanding of pain?
26:22-31:03: What is the DOLOReS platform?
31:03-32:37: Delivery methods
32:37-33:55: Keeping costs low
33:55-34:58: Next steps


Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 


Stay updated by subscribing to our newsletter

Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. 
Its mission is to use CRISPR technology to bring back extinct animals, such as the mammoth, the thylacine, and the dodo.


Since DNA was recovered in 2021 from mammoths frozen in the Arctic tundra, the company has been working on splicing bits of the recovered DNA into the genome of its closest relative, the Asian elephant, as it shares 99.6% of its DNA. 

Ben Lamm, co-founder and CEO of Colossal Biosciences spoke with us about the company’s plans.

01:03-02:57: Introduction to Ben Lamm
02:57-04:26: About Colossal Biosciences
04:26-09:35: What techniques are used to tackle de-extinction?
09:35-13:48: What are the biggest challenges?
13:48-14:57: What tools do you need to ‘build’ an extinct species? 
14:57-19:17: How do you address not adversely affecting ecosystems?
19:17-22:22: How do you take on negativity over your de-extinction work?
22:22-23:26: Reintroducing existing species into previous habitats?
23:26-24:06: Does this extend to critically endangered species?
24:06-25:54: Why is there a lot of interest in de-extinction?
25:54-28:10: How do you ensure we don’t repeat the same patterns of extinction?
28:10-29:38: Can you address the loss of current species?
29:38-30:35: How can you help solve the loss of species?
30:35-33:48: Addressing the challenges of introducing different species?
33:48-35:22: Transparency through documentaries
35:22-37:27: 2028 goal for mammoth calves

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

It would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way.
Recently, Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) announced a global collaboration and exclusive option-to-license agreement. This is to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, a novel G protein-coupled receptor (GPCR) target. The goal is to improve patient outcomes by addressing the positive, negative, and cognitive symptoms of schizophrenia.


Clíona MacSweeney, Sosei Heptares’ GPR52 program leader, spoke with us about that partnership, as well as other developments in the field of schizophrenia treatments.

00:57-03:44: What is schizophrenia?
03:44-04:52: What are the current schizophrenia treatments?
04:52-06:27: Why is schizophrenia challenging to treat?
06:27-07:34: Why is 2024 a big year for schizophrenia treatments?
07:34-08:56: Seratonin and dopamine modulation
08:56-10:46: How does muscarinic modulation work?
10:46-12:35: Excitatory and inhibitory tone pipeline 
12:35-14:12: Digital therapeutic and epigenetic modulation
14:12-16:12: GPR52 agonists
16:12-17:53: How are GPR52 agonists different?
17:53-19:03: Are there lots of schizophrenia treatments coming?
19:03-20:10: Will some new schizophrenia treatments be used in conjunction with existing treatments?
20:10-20:49: Is a schizophrenia cure possible?
20:49-21:22: Treatment frequency
21:22-22:21: Where is Sosei Heptares with clinical trials for schizophrenia?
22:21-22:45: What else is in Sosei Heptares’ pipeline?
22:45-23:35: Sosei Heptares becoming Nxera
23:35-24:42: Schizophrenia conferences

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
 
Stay updated by subscribing to our newsletter

There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient.
Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. 

00:52-04:09: About Terran Biosciences
04:09-06:03: What are the challenges of using psychedelics?
06:03-07:32: Is there still a stigma attached to use of psychedelics? 
07:32-11:45: How do psychedelics work on the brain?
11:45-13:44: Why are psychedelics a good treatment?
13:44-16:51: What is Idazoxan XR?
16:51-18:01: How do you make changes to drugs?
18:01-21:19: How did you develop your business model?
21:19-22:40: What are Eplivanserin and Volinanserin?
22:40-24:49: How useful are repurposed drugs?
24:49-29:06: Keeping drugs affordable
29:06-30:31: Dealing with patents
30:31-32:41: What are empathogens?
32:41-33:12: Where is the company at with clinical trials?
33:12-35:45: What is NM-101?
35:45-37:47: How does Terran differ from other companies?
37:47-39:54: Are you looking to cure conditions?
39:54-40:48: Schizophrenia


Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. 
The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. 


In this week’s conversation, Noam Solomon, CEO and co-founder of Immunai, covers the data gap in drug discovery and how machine learning (ML) can solve it, how to de-risk early-stage drug discovery, predictions for AI, and more.


00:41-01:05: About Immunai
01:05-01:37: Why map the immune system?
01:37-02:36: Are you taking a step back to study the problem in order to move forward?
02:36-03:41: How difficult is it to map the immune system?
03:41-05:21: What is your AMICA platform?
05:21-07:16: Where does your data come from? 
07:16-09:01: How do you account for differences between patients?
09:01-11:27: What are the biggest challenges to drug development?
11:27-13:59: How can AI improve drug development?
13:59-14:47: Will AI advances speed up drug development?
14:47-15:58: Is the use of AI applicable in all diseases and conditions?
15:58-17:40: What sets your approach apart from other companies using AI?
17:40-18:46: What partnerships does Immunai have? 
18:46-20:16: What are pharma companies looking for from Immunai?
20:16-23:09: How can AI help with clinical trials?
23:09-24:24: Can AI help with preventative care?
24:24-26:22: Google Maps for the immune system
26:22-27:10: What will we see from AI in drug discovery in the short term? 
27:10-27:58: What are the next steps for Immunai?


Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
Stay updated by subscribing to our newsletter